ArticleBMC nephrology2025
Successful application of innovative hybrid anticoagulation in continuous renal replacement therapy for an ultra-elderly patient: a case report.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEffective anticoagulation is essential for maintaining extracorporeal circuit patency during continuous renal replacement therapy (CRRT), yet commonly used anticoagulants have limitations. Herein, we present an innovative hybrid anticoagulation strategy for CRRT. CASE PRESENTATION: A 98-year-old female admitted with a left sacroiliac joint abscess developed decompensated heart failure and acute kidney injury, necessitating CRRT. Conventional-dose regional citrate anticoagulation (RCA) was projected to be intolerable in this ultra-elderly patient with progressive hepatic dysfunction, coagulopathy, and hyperlactatemia, whereas low-dose RCA failed to prevent filter clotting within hours. A modified anticoagulation protocol combining low-dose citrate with nafamostat infusion successfully sustained extracorporeal circuit patency without citrate-related metabolic complications or bleeding. Despite this success, the patient ultimately died of unrelated respiratory failure.
conclusionThe innovative hybrid anticoagulation strategy effectively prolonged CRRT circuit longevity in an ultra-elderly patient at high risk of citrate accumulation without procedure-associated complications. This approach represents a promising alternative for patients who have contraindications to conventional citrate anticoagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.